EGFR-IN-163

EGFR-IN-163 (Compound 13) is a competitive epidermal growth factor receptor (EGFR) inhibitor (IC50=0.079 μM, selective for HER-2 inhibition) . EGFR-IN-163 induces tumor cell apoptosis and cell cycle arrest at G₂/M phase. EGFR-IN-163 is promising for research of estrogen receptor-positive (ER+) breast cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; EGFR

Related Pathways

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

COC(C1=CC(C2=CN(C3=CC=C(OCCCCCCCC)C=C3)N=N2)=NC(C4=CN(C5=CC=C(OCCCCCCCC)C=C5)N=N4)=C1)=O

Molecular Formula

C39H49N7O4

Molecular Weight

679.85

References & Citations

[1]Khalaf Alshamari A, et al. Revealing the Anti-Cancer Potential of 1, 2, 3-Triazole-Isonicotinate Derivatives Targeting EGFR Kinase Inhibition in MCF-7 Cancer Cells: Design, Synthesis, Biological Evaluation, and In Silico Studies[J]. Polycyclic Aromatic Compounds, 2025: 1-22.